drugset / Trial / NCT00530530
ASP8825 - Study in Patients With Restless Legs Syndrome
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To demonstrate the superiority of ASP8825 over placebo and the dose response in patients with restless legs syndrome
Timeline
- Start
- 2007-09
- Primary completion
- 2009-01
- Completion
- 2009-01
Outcome
Met primary endpoint
paper Williams' multiple comparison test showed that only 1200 mg GEn was superior to placebo (p = 0.011). PMID 23121149 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | gabapentin enacarbil | Small molecule | 600 mg | Oral |
| Subject | gabapentin enacarbil | Small molecule | 900 mg | Oral |
| Subject | gabapentin enacarbil | Small molecule | 1200 mg | Oral |